Treatment and supportive care
Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
The treatment of these lymphomas is as intensive as it would be in anyone else, and that is the whole point of the last thirty years of progress.
What makes it specialized is everything arranged around the chemotherapy: which antiretrovirals, which prophylaxis, and which complications are prevented in advance.
Related pages: AIDS-related lymphoma
The bottom line
- Chemotherapy is given at full dose with curative intent.
- Antiretroviral therapy continues throughout treatment.
- Some antiretrovirals interact dangerously with chemotherapy and are changed first.
- Infection prophylaxis and tumour lysis prevention are mandatory rather than optional.
- The optimal chemotherapy regimen for several of the rarer subtypes.
- How best to use CAR-T and transplant in relapsed disease in people with HIV.
The story, step by step
What the evidence labels mean
Which regimen, for which subtype
What happens
Treatment is chosen by subtype, and the differences are substantial.
What the research shows
- Diffuse large B-cell lymphoma: either infusional EPOCH with rituximab, or standard R-CHOP. Both combine several chemotherapy drugs with the antibody rituximab.
- Burkitt lymphoma: dose-adjusted EPOCH-R is widely used and achieves high cure rates with less toxicity than older intensive regimens such as CODOX-M/IVAC. Treatment for Burkitt starts urgently.
- Plasmablastic lymphoma and primary effusion lymphoma: rituximab is omitted because these cells lack CD20 for it to bind. Dose-adjusted EPOCH is used, sometimes with bortezomib, and stem cell transplant is considered in people fit enough.
- Primary CNS lymphoma: high-dose methotrexate-based treatment, given with antiretroviral therapy.
- Hodgkin lymphoma: standard Hodgkin chemotherapy, given alongside antiretroviral therapy.
Why it matters
Rituximab is included or omitted based on whether the cells carry CD20, which is one of the first things the pathology report answers.
What's still uncertain
- Direct comparisons between regimens in HIV-associated lymphoma are limited.
Read more
- NCI: AIDS-related lymphoma treatmentGovernment
Next: Rituximab
A settled question that used to be contested
What happens
This deserves its own section because the advice changed and older material still reflects the old position.
What the research shows
- Rituximab is an antibody against CD20, a marker on most B-cells, and it substantially improves outcomes in CD20-positive lymphomas.
- An early randomized trial raised concern that adding it caused more deaths from infection in people with CD4 counts below 50.
- Subsequent studies, with modern prophylaxis and infusional regimens, supported its use even at low CD4 counts.
- It is now routinely included for CD20-positive lymphomas, with careful monitoring and infection prophylaxis.
- It must not be given to someone with hepatitis B without antiviral cover, because it can cause severe reactivation.
Why it matters
If you read that rituximab is avoided in advanced HIV, that reflects a concern from the early 2000s that has since been resolved.
What's still uncertain
- Caution remains appropriate at very low CD4 counts and treatment is individualized.
Read more
- NCI: AIDS-related lymphoma treatmentGovernment
Next: The interactions
Which HIV drugs must change
What happens
This is the most specialized part of treating these lymphomas and the most important safety issue.
What the research shows
- Ritonavir and cobicistat are boosters that work by blocking the liver enzyme CYP3A4. That is exactly the enzyme that clears several chemotherapy drugs.
- Blocking it causes chemotherapy levels to rise sharply. With vinca alkaloids such as vincristine this can produce severe, sometimes irreversible nerve damage, and it also raises exposure to cyclophosphamide and etoposide.
- These boosters are therefore avoided during chemotherapy, and the HIV regimen is usually switched to an unboosted integrase inhibitor such as dolutegravir, bictegravir or raltegravir.
- Zidovudine is also avoided because it suppresses the bone marrow, which chemotherapy already does.
- Some other antiretrovirals induce rather than inhibit liver enzymes, which can lower chemotherapy levels instead. Every regimen is reviewed before treatment starts.
Why it matters
The HIV regimen is usually changed before chemotherapy begins. If nobody has mentioned that, it is worth asking about specifically.
What's still uncertain
- Interaction data for newer agents is still accumulating, and pharmacist review is standard practice.
Read more
- Clinicalinfo (NIH): Adult and adolescent ARV guidelinesGovernment
- NCI: AIDS-related lymphoma treatmentGovernment
Next: Prophylaxis
What is prevented rather than treated
What happens
A specific list of things given routinely, because treating them after they happen goes much worse.
What the research shows
- Pneumocystis jirovecii pneumonia prophylaxis with co-trimoxazole, given during chemotherapy regardless of CD4 count, because chemotherapy causes its own immunosuppression.
- Antiviral cover for anyone who is a hepatitis B carrier, with entecavir or tenofovir, before rituximab.
- Granulocyte colony-stimulating factor, G-CSF, to shorten the period of low white cell counts after each cycle.
- Tumour lysis syndrome prevention with aggressive fluids and either allopurinol or rasburicase, particularly in Burkitt lymphoma. Rasburicase must not be given to people with G6PD deficiency, in whom it causes severe red cell breakdown, so this is checked first.
- Central nervous system prophylaxis, usually chemotherapy given into the spinal fluid, for Burkitt lymphoma and high-risk large B-cell lymphoma.
- Antifungal and antiviral prophylaxis in some situations, depending on the regimen and CD4 count.
Why it matters
Tumour lysis prevention is started before the first dose, not after, because the danger is greatest when the treatment works fastest.
What's still uncertain
- Prophylaxis regimens vary between centres and are individualized.
Read more
- Clinicalinfo (NIH): Guidelines for opportunistic infections in adults with HIVGovernment
- NCI: AIDS-related lymphoma treatmentGovernment
Next: The rest of care
What else belongs in the plan
What happens
Several things matter as much as the drug list and are easier to arrange early.
What the research shows
- Fertility preservation, discussed before treatment starts rather than after.
- Nutrition support, since weight loss is common and affects tolerance of treatment.
- Dental assessment before chemotherapy, particularly with oral involvement.
- Mental health and social support. A cancer diagnosis on top of HIV, often with existing stigma and isolation, is a heavy combination, and support is part of treatment.
- For relapsed disease, autologous stem cell transplant and CAR-T cell therapy are both now used in people with HIV, who were historically excluded from such treatments and from the trials that established them.
- Clinical trial participation is worth asking about at diagnosis, not only at relapse.
Why it matters
People with HIV were excluded from cancer trials for decades. That has changed, and it is worth knowing when asking about options.
What's still uncertain
- Access to transplant and CAR-T for people with HIV still varies between centres.
Read more
More plain-language reading
- OwieClear: The subtypesOwieClear
- OwieClear: Clinical presentation and diagnosisOwieClear
- OwieClear: Preventing lymphoma in HIVOwieClear